Is Alzheimer’s Disease a Liver Disease of the Brain?
Open accessThe DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
Clinical specialization is not only a force for progress, but it has also led to the fragmentation of medical knowledge. The focus of research in the field of Alzheimer's disease (AD) is neurobiology, while hepatologists focus on liver diseases and lipid specialists on atherosclerosis. This article on AD focuses on the role of the liver and lipid homeostasis in the development of AD. Amyloid-β (Aβ) deposits accumulate as plaques in the brain of an AD patient long before cognitive decline is evident. Aβ generation is a normal physiological process; the steady-state level of Aβ in the brain is determined by balance between Aβ production and its clearance. We present evidence suggesting that the liver is the origin of brain Aβ deposits and that it is involved in peripheral clearance of circulating Aβ in the blood. Hence the liver could be targeted to decrease Aβ production or increase peripheral clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig.1 Some factors altering the balance between amyloid Aβ production and clearance leading to dyshomeostasis. Peripheral clearance can remove 40–50% of Aβ burden in the brain [25, 26]. Aβ, amyloid-β; AβPP, amyloid-β protein precursor, LRP1, low-density lipoprotein receptor-related peptide 1; LDLR, low-density-lipoprotein receptor; P-gp, P-glycoprotein.](https://figures.cochat.ai/paper-figures/06233310ef5d43cd8f768f053c5fa4bf/is-alzheimers-disease-a-liver-disease-of-the-brain-figure-1.jpg)
![Fig.2 Schematic representation of Alzheimer’s disease homeostasis showing amyloid-β (Aβ) production from amyloid-β protein precursor (AβPP) in the liver, dysregulated influx/efflux across blood-brain barrier (BBB) (1), transport in serum via soluble LRP1 (2) and exosomes [61] and saturable uptake of Aβ by liver via low-density lipoprotein receptor-related peptide 1 (LRP1) and low-density-lipoprotein receptor (LDLR) (3) with subsequent biliary clearance. RAGE, receptor for advanced glycation end products.](https://figures.cochat.ai/paper-figures/686adf0fd74c48389a6937bd7a50f794/is-alzheimers-disease-a-liver-disease-of-the-brain-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this capacity decreases with age, which is partially attributed to the low expression of low-density lipoprotein receptor-related protein 1 (LRP-1) in hepatocytes.227–229”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [228]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“typified by deposition of A within the brain [3, 4].”
BackgroundSleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411 · cited 1×
“Studies on sleep raise the possibility that altering sleep quality might impact A deposition and may also regulate the clearance of A from the brain [63].”
BackgroundQuerfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · cited 1×
“typified by deposition of A within the brain [3, 4].”
BackgroundApolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“A number of subsequent studies suggest that ApoE4 inhibits A clearance and/or is less efficient in mediating A peripheral clearance compared with ApoE3 and ApoE2 [47] (reviewed in [48, 49]).”
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Alzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Deaths: Leading Causes for 2017.
Heron, M. P. (2019) · PubMed · Cited by 2,108
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611 · cited 13×
“HCV may cross the BBB leading to neuroinflammation and neuropsychiatric symptoms [115].”
BackgroundInfluentialThe glymphatic pathway in neurological disorders.
Rasmussen, M. K., Mestre, H., & Nedergaard, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30318-1 · Cited by 1,560 · cited 1×
“These lymphatic vessels exit the cranium along veins and arteries associated with the middle meningeal arteries, transporting waste via the deep cervical lymph nodes to the systemic circulation (reviewed in [68]).”
BackgroundImpairment of paravascular clearance pathways in the aging brain
Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24271 · Cited by 1,521 · cited 1×
“The clearance of amyloid from the brain during sleep is primarily via the glymphatic pathway [66, 67].”
BackgroundInotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452 · cited 1×
“Both Patirisan, an siRNA and Inotersen, an untargeted ASO, are approved by the FDA and EC for this disorder [102].”
BackgroundThe current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443 · cited 1×
“The last decade has witnessed renewed interest in novel therapeutic agents aiming to prevent the production of disease-causing proteins at the level of mRNA, reviewed in [97].”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“These include clearance via the glial-lymphatic (glymphatic) system [28] and transport across the BBB, mediated by lowdensity lipoprotein receptor-related peptide 1 (LRP1) [29, 30] and the low-density-lipoprotein receptor (LDLR).”
BackgroundAlzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343 · cited 1×
“Generation of the A PP by - and -secretases occurs in early endosomes, followed by routing of A to multivesicular bodies in HeLa and N2a cells and subsequently, a minute fraction of A peptides can be secreted from the cells in association with exosomes [16].”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy
Shao, H., Chung, J., Balaj, L., Charest, A., Bigner, D. D., Carter, B. S., Hochberg, F. H., Breakefield, X. O., Weissleder, R., & Lee, H. (2012) · Nature Medicine · doi:10.1038/nm.2994 · Cited by 759 · cited 13×
“HCV may cross the BBB leading to neuroinflammation and neuropsychiatric symptoms [115].”
BackgroundInfluentialAPOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714 · cited 1×
“Thus, at age 85 years, the lifetime risk of AD without reference to APOE genotype is 11% in males and 14% in females, compared to 51% for male APOE4 homozygotes and 60% for female APOE4 homozygotes, consistent with autosomal co-dominant inheritance of a moderately penetrant gene variant [45].”
BackgroundMahmoudianDehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xie, G., Louie, G., Kueider‐Paisley, A., Moseley, M. A., Thompson, J. W., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.217 · Cited by 706
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672 · cited 1×
“The BBB keeps neurotoxic plasma derived components out of the central nervous system, but recent studies suggest an early BBB breakdown in AD [19].”
BackgroundDeane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease
Musiek, E. S., Xiong, D. D., & Holtzman, D. M. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.121 · Cited by 529 · cited 2×
“A rapidly growing body of research suggests that disturbances in the circadian system precede the emergence of the characteristic cognitive and motor symptoms of AD [62].”
BackgroundAlzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · cited 1×
“They can carry cargo across the BBB [17] and are carriers of A in AD [18].”
BackgroundPermanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477
A Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467 · cited 1×
“Mutations in these loci result in abnormal processing of A PP and increased generation of A 42, which aggregates as insoluble -pleated sheets [5].”
BackgroundDrug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459 · cited 1×
“The aim of the G8 summit held in London in 2013 was “to create disease modifying treatment to stop, slow, or reverse the condition”, but, under the current conditions, only drugs currently in late phase I or later will have a chance of being approved by 2025 [74].”
BackgroundApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449 · cited 2×
“A number of subsequent studies suggest that ApoE4 inhibits A clearance and/or is less efficient in mediating A peripheral clearance compared with ApoE3 and ApoE2 [47] (reviewed in [48, 49]).”
BackgroundPalmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
Schwarzman, A. L., Gregori, L., Vitek, M. P., Lyubski, S., Strittmatter, W. J., Enghilde, J. J., Bhasin, R., Silverman, J., Weisgraber, K. H., & Coyle, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8368 · Cited by 413
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390
Robles, M. S., Cox, J., & Mann, M. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004047 · Cited by 383 · cited 1×
“of liver-specific metabolic pathways [71].”
An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease
Zhang, J., Chen, C., Hua, S., Liao, H., Wang, M., Xiong, Y., & Cao, F. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.024 · Cited by 376 · cited 1×
“metabolic syndrome and type 2 diabetes [119] [120]”
BackgroundSignaling by Nuclear Receptors
Sever, R., & Glass, C. K. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016709 · Cited by 374 · cited 3×
“The RXR agonist, bexarotene (brand name: Targretin), which is approved by both the FDA and European Medicines Agency (EMA) for use in cutaneous T cell lymphoma, stimulates physiological A clearance mechanisms, resulting in the rapid reversal of a broad range of A -induced deficits in mouse models [90].”
BackgroundClearance of amyloid-β by circulating lipoprotein receptors
Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., Pendu, R., Marky, A., Lenting, P. J., Wu, Z., Zarcone, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1635 · Cited by 373
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355
Nho, K., Kueider‐Paisley, A., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmüller, G., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.012 · Cited by 343 · cited 1×
“In addition, serum-based bile acid metabolites are associated with AD biomarkers, providing further evidence that bile acid pathways play a role in AD pathophysiology [56].”
BackgroundWiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 333
Kim, D.-G., Krenz, A., Toussaint, L. E., Maurer, K. J., Robinson, S.-A., Yan, A., Torres, L., & Bynoe, M. S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0467-5 · Cited by 330 · cited 1×
“diet and elevated brain and serum A 42 have been observed [122], and NALFD induces signs of AD in wild-type mice and accelerates pathological signs of AD [123].”
BackgroundMauvoisin, D., Wang, J., Jouffe, C., Martin, E., Atger, F., Waridel, P., Quadroni, M., Gachon, F., & Naef, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314066111 · Cited by 329
Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease
DemGene, Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O. T., Gudjonsson, S. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3246 · Cited by 324
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285 · cited 1×
“The A PP gene is located at chromosome 21q21 and individuals with Down’s syndrome, which results from trisomy of chromosome 21, develop AD neuropathology (reviewed in [13]).”
BackgroundXiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., Zhu, X.-Y., Giunta, B., Tan, J., Song, W.-H., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1477-1 · Cited by 277 · cited 3×
“In a murine model of AD using parabiosis (the anatomical joining of two animals for physiological research), it has been shown that parabiosis reduces brain A burden through clearance by peripheral tissues and organs, including the liver [26].”
BackgroundInfluentialDiabetes Mellitus and the Risk of Alzheimer’s Disease: A Nationwide Population-Based Study
Huang, C.-C., Chung, C.-M., Leu, H.-B., Lin, L.-Y., Chiu, C.-C., Hsu, C.-Y., Chiang, C.-H., Huang, P.-H., Chen, T.-J., Lin, S.-J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087095 · Cited by 265 · cited 1×
“metabolic syndrome and type 2 diabetes [119] [120]”
BackgroundZlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Amyloid‐β efflux from the central nervous system into the plasma
Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254
Mackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242 · cited 14×
“HCV may cross the BBB leading to neuroinflammation and neuropsychiatric symptoms [115].”
BackgroundInfluentialNho, K., Kueider-Paisley, A., Ahmad, S., MahmoudianDehkordi, S., Arnold, M., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.7978 · Cited by 227
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
Elia, A. E., Lalli, S., Monsurrò, M. R., Sagnelli, A., Taiello, A. C., Reggiori, B., La Bella, V., Tedeschi, G., & Albanese, A. (2016) · European Journal of Neurology · doi:10.1111/ene.12664 · Cited by 225
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221 · cited 1×
“elicited robust gene silencing in vivo [100].”
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 221 · cited 1×
“A number of subsequent studies suggest that ApoE4 inhibits A clearance and/or is less efficient in mediating A peripheral clearance compared with ApoE3 and ApoE2 [47] (reviewed in [48, 49]).”
Song, Q., Huang, M., Yao, L., Wang, X., Gu, X., Chen, J., Chen, J., Huang, J., Hu, Q., Kang, T., et al. (2014) · ACS Nano · doi:10.1021/nn4058215 · Cited by 219 · cited 1×
“A biologically inspired nanostructure, ApoE3reconstituted high-density lipoprotein, with high binding affinity to A , rescues memory loss of mice with AD by accelerating the clearance of A [50].”
BackgroundDeaths: Leading Causes for 2014.
Heron, M. P. (2016) · PubMed · Cited by 213
Jim, K. K., Engelen-Lee, J., van der Sar, A. M., Bitter, W., Brouwer, M. C., van der Ende, A., Veening, J.-W., van de Beek, D., & Vandenbroucke-Grauls, C. M. J. E. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0655-y · Cited by 212
Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition
Lim, C. Z. J., Zhang, Y., Chen, Y., Zhao, H., Stephenson, M. C., Ho, N. R. Y., Chen, Y., Chung, J., Reilhac, A., Loh, T. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09030-2 · Cited by 209 · cited 2×
“Schematic representation of Alzheimer’s disease homeostasis showing amyloid- (A ) production from amyloid- protein precursor (A PP) in the liver, dysregulated influx/efflux across blood-brain barrier (BBB) (1), transport in serum via soluble LRP1 (2) and exosomes [61] and saturable uptake of A by liver via low-density…”
BackgroundThe Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases
Vang, S., Longley, K., Steer, C. J., & Low, W. C. (2014) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.017 · Cited by 201
Gleevec inhibits β-amyloid production but not Notch cleavage
Netzer, W. J., Dou, F., Cai, D., Veach, D., Jean, S., Li, Y., Bornmann, W. G., Clarkson, B., Xu, H., & Greengard, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534745100 · Cited by 194
Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193
Comorbidity and dementia: A nationwide survey in Taiwan
Chen, T.-B., Yiao, S.-Y., Sun, Y., Lee, H.-J., Yang, S.-C., Chiu, M.-J., Chen, T.-F., Lin, K.-N., Tang, L.-Y., Lin, C.-C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0175475 · Cited by 175
Kim, C.-W., Yun, K. E., Jung, H.-S., Chang, Y., Choi, E.-S., Kwon, M.-J., Lee, E.-H., Woo, E. J., Kim, N. H., Shin, H., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.035 · Cited by 172 · cited 7×
“Hepatic insulin resistance is associated with NAFLD and is a major factor in the pathogenesis of type 2 diabetes and the metabolic syndrome [118].”
BackgroundInfluentialSpecialization, Subspecialization, and Subsubspecialization in Internal Medicine
Cassel, C. K., & Reuben, D. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1012647 · Cited by 170 · cited 1×
“Clinical specialization, subspecialization, and subsubspecialization has some advantages in terms of creating standards but could be said to be leading to a growing fragmentation of medical care [125].”
BackgroundBoespflug, E. L., & Iliff, J. J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.11.031 · Cited by 168
Zissimopoulos, J. M., Barthold, D., Brinton, R. D., & Joyce, G. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3783 · Cited by 163 · cited 1×
“molecule, sex, and race/ethnicity [39].”
Plasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156 · cited 1×
“Interestingly low plasma levels of ApoE are associated with increased risk of future AD and all dementia in the general population, independent of 2/ 3/ 4 APOE genotype [117].”
BackgroundCastellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., Paoletti, A. C., Kasper, T. R., DeMattos, R. B., Zlokovic, B. V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206446109 · Cited by 154
Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors
Shin, D., & Wang, L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_236 · Cited by 149 · cited 1×
“Bile acids (chenodeoxycholic acid and cholic acid) are physiological ligands/activators of the nuclear receptors, farnesoid-X-receptor, pregnane-Xreceptor (PXR) and constitutive androstane receptor, while lithocholic acid is a ligand for the Vitamin D receptor (VDR) and PXR [82].”
BackgroundThe unfolded protein response: mechanisms and therapy of neurodegeneration
Smith, H. L., & Mallucci, G. R. (2016) · Brain · doi:10.1093/brain/aww101 · Cited by 144 · cited 1×
“didate to combat neurodegenerative diseases [73].”
Sagare, A. P., Deane, R., & Zlokovic, B. V. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.008 · Cited by 143
Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease
Fitzgerald, E., Murphy, S., & Martinson, H. A. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00369 · Cited by 143
Hepatitis C virus infection, and neurological and psychiatric disorders – A review
Yarlott, L., Heald, E., & Forton, D. M. (2016) · Journal of Advanced Research · doi:10.1016/j.jare.2016.09.005 · Cited by 138 · cited 1×
“HCV may cross the BBB leading to neuroinflammation and neuropsychiatric symptoms [115].”
BackgroundLee, J.-Y., Acosta, E. G., Stoeck, I. K., Long, G., Hiet, M.-S., Mueller, B., Fackler, O. T., Kallis, S., & Bartenschlager, R. (2014) · Journal of Virology · doi:10.1128/jvi.01660-14 · Cited by 126 · cited 1×
“ApoE, a critical player in A homeostasis, is intimately involved in production of infectious HCV particles [114] and is important in HCV cell entry.”
BackgroundBACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
Lo, A. C., Callaerts-Vegh, Z., Nunes, A. F., Rodrigues, C. M. P., & D'Hooge, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.003 · Cited by 120 · cited 1×
“and pre-frontal amyloid deposition [80].”
Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Liver as a target for oligonucleotide therapeutics
Sehgal, A., Vaishnaw, A., & Fitzgerald, K. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.045 · Cited by 115
Cabrera, D., Arab, J. P., & Arrese, M. A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_241 · Cited by 115 · cited 1×
“Therapies which could be repurposed include both licensed drugs and herbal remedies, for example: Tauroursodeoxycholic acid (TUDCA) is the taurine conjugate of ursodeoxycholic acid (UDCA), a US Food and Drug Administration (FDA)-approved hydrophilic bile acid for the treatment of certain cholestatic liver diseases [77…”
BackgroundGlymphatics visualization after focused ultrasound-induced blood-brain barrier opening in humans
Meng, Y., Abrahao, A., Heyn, C. C., Bethune, A. J., Huang, Y., Pople, C. B., Aubert, I., Hamani, C., Zinman, L., Hynynen, K., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25604 · Cited by 114 · cited 1×
“More recent research has demonstrated glymphatic efflux in patients with AD [69].”
Backgroundvan de Sluis, B., Wijers, M., & Herz, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000411 · Cited by 108
Pioglitazone for the treatment of Alzheimer’s disease
Galimberti, D., & Scarpini, E. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1265504 · Cited by 106 · cited 1×
“A phase II study of pioglitazone in AD showed that it is safe and well tolerated and two large phase III trials are ongoing [86].”
BackgroundSutcliffe, J. G., Hedlund, P. B., Thomas, E. A., Bloom, F. E., & Hilbush, B. S. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22603 · Cited by 105
Alemi, M., Gaiteiro, C., Ribeiro, C. A., Santos, L. M., Gomes, J. R., Oliveira, S. M., Couraud, P.-O., Weksler, B., Romero, I., Saraiva, M. J., et al. (2016) · Scientific Reports · doi:10.1038/srep20164 · Cited by 104
Guo, Y.-X., He, L., Zhang, M., Wang, F., Liu, F., & Peng, W. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.041 · Cited by 103
Bonet-Costa, V., Herranz-Pérez, V., Blanco-Gandía, M., Mas-Bargues, C., Inglés, M., Garcia-Tarraga, P., Rodriguez-Arias, M., Miñarro, J., Borras, C., Garcia-Verdugo, J. M., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151020 · Cited by 103
Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease
Jarrett, K. E., Lee, C. M., Yeh, Y.-H., Hsu, R. H., Gupta, R., Zhang, M., Rodriguez, P. J., Lee, C. S., Gillard, B. K., Bissig, K.-D., et al. (2017) · Scientific Reports · doi:10.1038/srep44624 · Cited by 97 · cited 1×
“In murine models, liver-directed somatic genome editing with CRISPR-Cas9 is a novel and versatile approach with therapeutic potential in metabolic disorders [103].”
BackgroundSkerrett, R., Pellegrino, M. P., Casali, B. T., Taraboanta, L., & Landreth, G. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.652008 · Cited by 94
Hepatitis C viral infection and the risk of dementia
Chiu, W. ‐., Tsan, Y. ‐., Tsai, S. ‐., Chang, C. ‐., Wang, J. ‐., Chen, P. ‐., & Health Data Analysis in Taiwan (hDATa) Research Group (2014) · European Journal of Neurology · doi:10.1111/ene.12317 · Cited by 90
Sagare, A. P., Deane, R., Zetterberg, H., Wallin, A., Blennow, K., & Zloković, B. V. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101248 · Cited by 88
Dietary glycotoxins exacerbate progression of experimental fatty liver disease
Leung, C., Herath, C. B., Jia, Z., Goodwin, M., Mak, K. Y., Watt, M. J., Forbes, J. M., & Angus, P. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.033 · Cited by 88 · cited 7×
“Hepatic insulin resistance is associated with NAFLD and is a major factor in the pathogenesis of type 2 diabetes and the metabolic syndrome [118].”
BackgroundInfluentialBjursell, M., Porritt, M. J., Ericson, E., Taheri‐Ghahfarokhi, A., Clausen, M., Magnusson, L. U., Admyre, T., Nitsch, R., Mayr, L. M., Aasehaug, L., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.02.015 · Cited by 88
Lubitz, I., Ricny, J., Atrakchi‐Baranes, D., Shemesh, C., Kravitz, E., Liraz‐Zaltsman, S., Maksin‐Matveev, A., Cooper, I., Leibowitz, A., Uribarri, J., et al. (2016) · Aging Cell · doi:10.1111/acel.12436 · Cited by 84
MURATA, N., MURAKAMI, K., OZAWA, Y., KINOSHITA, N., IRIE, K., SHIRASAWA, T., & SHIMIZU, T. (2010) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.100524 · Cited by 82
Apolipoprotein E influences amyloid-beta clearance from the murine periphery
Hone, E., Martins, I., Fonte, J., & Martins, R. N. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5101 · Cited by 78 · cited 11×
“ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator-activated receptor gamma (PPAR ) and liver X receptor (LXR) in coordination with retinoid X receptors (RXRs).”
BackgroundInfluentialImpaired hepatic amyloid-beta degradation in Alzheimer’s disease
Maarouf, C. L., Walker, J. E., Sue, L. I., Dugger, B. N., Beach, T. G., & Serrano, G. E. (2018) · PLOS ONE · doi:10.1371/journal.pone.0203659 · Cited by 75 · cited 1×
“The authors conclude that their results “support the possibility that impaired hepatic A degradation could be a factor contributing to increased brain A accumulation and AD” [55].”
BackgroundKatsouri, L., & Georgopoulos, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021880 · Cited by 72 · cited 1×
“In animal models of AD, lack of LDLR enhances amyloid deposition in the brain [31], while LDLR overexpression increases the rate that A enters the blood from the brain [32].”
BackgroundGoodman, J. R., Adham, Z. O., Woltjer, R. L., Lund, A. W., & Iliff, J. J. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.07.020 · Cited by 70
Bateman, R. J., Blennow, K., Doody, R., Hendrix, S., Lovestone, S., Salloway, S., Schindler, R., Weiner, M., Zetterberg, H., Aisen, P., et al. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.21 · Cited by 63 · cited 1×
“Plasma A levels tend to be nearer the lower limits of detection, but there is emerging consensus that “recent improvements in technologies to assess plasma levels of amyloid beta indicate that a single sample of blood could provide an accurate estimate of brain amyloid positivity” [57].”
BackgroundEffects of pioglitazone on the incidence of dementia in patients with diabetes
Chou, P., Ho, B., & Yang, Y. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.006 · Cited by 61 · cited 1×
“In patients with diabetes, pioglitazone treatment is a time- and dose-dependent protective factor against dementia [87].”
BackgroundSILK studies — capturing the turnover of proteins linked to neurodegenerative diseases
Paterson, R. W., Gabelle, A., Lucey, B. P., Barthélemy, N. R., Leckey, C. A., Hirtz, C., Lehmann, S., Sato, C., Patterson, B. W., West, T., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0222-0 · Cited by 61 · cited 1×
“Indeed, sleep has been identified as a factor which alters the production and/or clearance of A in stable isotope labelling kinetic (SILK) studies measuring A turnover in blood and within the brain [64].”
BackgroundSharman, M. J., Morici, M., Hone, E., Berger, T., Taddei, K., Martins, I. J., Lim, W. L. F., Singh, S., Wenk, M. R., Ghiso, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100141 · Cited by 54
Silymarin’s Inhibition and Treatment Effects for Alzheimer’s Disease
Guo, H. W., Cao, H., Cui, X., Zheng, W., Wang, S., Yu, J., & Chen, Z. (2019) · Molecules · doi:10.3390/molecules24091748 · Cited by 54 · cited 1×
“Silymarin can control the production of A by inhibiting the precursor substance of A , A PP, and has potential for the treatment of AD [95].”
BackgroundPoduslo, J. F., Curran, G. L., Haggard, J. J., Biere, A. L., & Selkoe, D. J. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0132 · Cited by 52
Zolezzi, J. M., BastÃas-Candia, S., Santos, M. J., & Inestrosa, N. C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00176 · Cited by 52
Moon, J. H., Kang, S. B., Park, J. S., Lee, B. W., Kang, E. S., Ahn, C. W., Lee, H. C., & Cha, B. S. (2011) · Metabolism · doi:10.1016/j.metabol.2010.08.013 · Cited by 50 · cited 1×
“protein-2 (SREBP-2) in vitro and in vivo [38].”
BackgroundNabers, A., Hafermann, H., Wiltfang, J., & Gerwert, K. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.01.008 · Cited by 48
Zheng, H. X., Cai, A., Shu, Q., Niu, Y., Xu, P., Li, C., Lin, L., & Gao, H. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00847 · Cited by 41 · cited 1×
“In addition, recent tissue-specific metabolomic analysis revealed that the liver was the earliest affected organ in A PP/PS1 mice during amyloid pathology progression [14].”
BackgroundSagare, A. P., Bell, R. D., Srivastava, A., Sengillo, J. D., Singh, I., Nishida, Y., Chow, N., & Zlokovic, B. V. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439570 · Cited by 40 · cited 1×
“Improving the binding of A to a sLRP1 variant has been shown to increase the efficiency of A clearance [34], suggesting that this binding prevents re-entry of A to the brain.”
BackgroundABCA7 loss-of-function variants, expression, and neurologic disease risk
Allen, M., Lincoln, S. J., Corda, M., Watzlawik, J. O., Carrasquillo, M. M., Reddy, J. S., Burgess, J. D., Nguyen, T., Malphrus, K., Petersen, R. C., et al. (2017) · Neurology Genetics · doi:10.1212/nxg.0000000000000126 · Cited by 37
Li, X., Wen, D., Zhao, Y., Yan-nan, H., & Mandell, M. S. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60058-2 · Cited by 36 · cited 1×
“protein 24 h after surgery [110], presumably reflect-”
BackgroundSagare, A. P., Winkler, E. A., Bell, R. D., Deane, R., & Zloković, B. V. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22670 · Cited by 35
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Mohamed, L. A., & Kaddoumi, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052514 · Cited by 32
Mandecka, M., Budziszewska, M., Barczak, A. K., Pepłońska, B., Chodakowska-Żebrowska, M., Filipek-Gliszczyńska, A., Nesteruk, M., Styczyńska, M., Barcikowska, M., & Gabryelewicz, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160176 · Cited by 31 · cited 1×
“Thus, studies showing significantly lower levels of CSF A 42 in AD patients with more severe cognitive impairment [65] are unable to provide information on changes in A turnover occurring either during the circadian cycle or during the progression of disease.”
BackgroundGleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage
Netzer, W. J., Bettayeb, K., Sinha, S. C., Flajolet, M., Greengard, P., & Bustos, V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620963114 · Cited by 29
Hu, Y., Yang, Y., Yu, Y., Wen, G., Shang, N., Zhuang, W., Lu, D., Zhou, B., Liang, B., Yue, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301913k · Cited by 28
Kim, H. J., Moon, J. H., Kim, H. M., Yun, M. R., Jeon, B. H., Lee, B., Kang, E. S., Lee, H. C., & Soo, B. (2013) · Metabolism · doi:10.1016/j.metabol.2013.09.006 · Cited by 25 · cited 1×
“Cilostazol enhances LRP1 expression in liver by activating PPAR through the peroxisome proliferator response element in the LRP1 promoter [88].”
BackgroundGrimmer, T., Goldhardt, O., Guo, L., Yousefi, B. H., Förster, S., Drzezga, A. E., Sorg, C., Alexopoulos, P., Förstl, H., Kurz, A., et al. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.01.016 · Cited by 23 · cited 1×
“In a human study using amyloid PET with [11C]PiB, the C667T polymorphism of the LRP1 gene has been shown to be moderately, but significantly associated with global and regional amyloid deposition [44].”
MethodImatinib treatment and Aβ42 in humans
Olsson, B., Legros, L., Guilhot, F., Strömberg, K., Smith, J. C., Livesey, F. J., Wilson, D. H., Zetterberg, H., & Blennow, K. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.08.283 · Cited by 22
Association between the characteristics of metabolic syndrome and Alzheimer’s disease
Yang, H.-T., Sheen, Y., Kao, C.-D., Chang, C.-A., Hu, Y.-C., & Lin, J.-L. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9406-2 · Cited by 21 · cited 1×
“diet and elevated brain and serum A 42 have been observed [122], and NALFD induces signs of AD in wild-type mice and accelerates pathological signs of AD [123].”
BackgroundProbing the role of PPARγ in the regulation of late-onset Alzheimer’s disease-associated genes
Barrera, J., Subramanian, S., & Chiba-Falek, O. (2018) · PLOS ONE · doi:10.1371/journal.pone.0196943 · Cited by 21
Making gene editing a therapeutic reality
Conboy, I. M., Murthy, N., Etienne, J., & Robinson, Z. R. (2018) · F1000Research · doi:10.12688/f1000research.16106.1 · Cited by 20
Hayashi, Y., & Jono, H. (2018) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00625 · Cited by 17 · cited 1×
“In this condition, mutant transthyretin is produced in the liver resulting in amyloid fibril deposition in various organs and heterogeneous clinical symptoms including peripheral neuropathy and cardiomyopathy [101].”
BackgroundQiu, Q., Shen, L., Jia, L., Wang, Q., Li, F., Li, Y., & Jia, J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181291 · Cited by 16
Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency
Sheridan, D. A., Bridge, S. H., Crossey, M. M. E., Felmlee, D. J., Thomas, H. C., Neely, R. D. G., Taylor-Robinson, S. D., & Bassendine, M. F. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9520-9 · Cited by 13 · cited 1×
“We have reported ApoE deficiency in HCV associated depression [116].”
BackgroundSelf-citationAntisense technology to lower LDL cholesterol
Neely, R. D. G., & Bassendine, M. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60364-9 · Cited by 10 · cited 1×
“was among the first such agents to be marketed [99].”
BackgroundSelf-citationToward In Vivo Gene Therapy Using CRISPR
Skipper, K. A., & Mikkelsen, J. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9170-9_18 · Cited by 8
CPEB4 links the clock and the UPR to protect the liver
Moore, P. C., & Oakes, S. A. (2017) · Nature Cell Biology · doi:10.1038/ncb3460 · Cited by 7 · cited 1×
“dian rhythm are intimately linked in the liver [72]”
Background
Cited by
Więckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“3, a leaky BBB contributes to accumulation of Aβ in the brain (Estrada et al., 2019; Bassendine et al., 2020).”
Virus exposure and neurodegenerative disease risk across national biobanks
Levine, K. S., Leonard, H. L., Blauwendraat, C., Iwaki, H., Johnson, N., Bandres-Ciga, S., Ferrucci, L., Faghri, F., Singleton, A. B., & Nalls, M. A. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.029 · Cited by 341
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Alzheimer’s disease as a viral disease: Revisiting the infectious hypothesis
Bruno, F., Abondio, P., Bruno, R., Ceraudo, L., Paparazzo, E., Citrigno, L., Luiselli, D., Bruni, A. C., Passarino, G., Colao, R., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102068 · Cited by 88
Couteur, D. G. L., Ngu, M., Hunt, N. J., Brandon, A. E., Simpson, S. J., & Cogger, V. C. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01099-z · Cited by 89
“…or dementia in people with type 2 diabetes aged 60 years or more 169 . β-Amyloid, the presumptive pathogenic protein in Alzheimer disease, might be cleared by the liver 170 or perhaps even produced by the liver 171 , providing a geroscience-based link between the ageing liver and dementia 172 .”
Metadata
- Authors
- Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D.
- Affiliations
- Imperial College London (GB)
- University Hospitals Coventry and Warwickshire NHS Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Corresponding author
- Bassendine, Margaret F.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2020-05-05
- Volume
- 75
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC7306895
- OpenAlex
- W3014127696
- Cited by
- 124
- References
- 129
- Citations by year
- 2026: 16 · 2025: 30 · 2024: 24 · 2023: 18 · 2022: 25 · 2021: 8 · 2020: 3
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research (2011-NIHR 7068)
- Imperial College London
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, liver
- MeSH terms
- Alzheimer Disease, Animals, Brain, Humans, Liver, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Metabolic Syndrome, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.